Event-free (A) and Overall (B) survival according to the occurrence of Grade 2 + LVSD, in the presence or absence of associated bloodstream infection, on COG trial AAML0531. Grade 2 + LVSD was defined as LVEF <50% or LVFS <24% based on Common Terminology Criteria for Adverse Events V3.0. Adapted with permission from Getz et al.⁶